USD 12.31
(-7.09%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Operating Cash Flow | -24.15 Million | -24.06 Million | -20.1 Million | -15.16 Million | -8.52 Million | -13.16 Million |
Net Income | -22.11 Million | -25.64 Million | -43.84 Million | -19.34 Million | -11.95 Million | -13.38 Million |
Depreciation & Amortization | 2.36 Million | 1.71 Million | 1.55 Million | 1.35 Million | 1.46 Million | 1.2 Million |
Deferred income taxes | 1.07 Million | - | 14.88 Million | 2.42 Million | -179.76 Thousand | - |
Stock-based compensation | 2.72 Million | 3.53 Million | 1.26 Million | 519 Thousand | 468.58 Thousand | 338.51 Thousand |
Change in working capital | -3.08 Million | 3.04 Million | 1.68 Million | -1.15 Million | 459.45 Thousand | -431.11 Thousand |
Other non-cash items | 4.48 Million | -6.71 Million | 4.34 Million | 1.03 Million | 1.22 Million | 2.59 Million |
Investing Cash Flow | -5.12 Million | -9.93 Million | -2.33 Million | -632.45 Thousand | -1.16 Million | -1.22 Million |
Investments in PPE | -5.12 Million | -111 Thousand | -117 Thousand | -632.45 Thousand | -16.82 Thousand | -1.22 Million |
Acquisitions | - | -5.42 Million | - | - | - | - |
Investment purchases | -4.66 Million | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | 4.66 Million | -4.39 Million | -2.21 Million | -632 Thousand | -1.14 Million | - |
Financing Cash Flow | 26.84 Million | 27.95 Million | 26.13 Million | 22.24 Million | 8.83 Million | 4.38 Million |
Debt repayment | -677 Thousand | -3.15 Million | -9.58 Million | -2.85 Million | -949.6 Thousand | -661.84 Thousand |
Dividends payments | - | - | -608 Thousand | - | - | - |
Common Stock Repurchased | - | - | -9.58 Million | - | - | - |
Common Stock Issuance | 26.17 Million | 22.5 Million | 16.54 Million | 21.53 Million | 2.97 Million | 5.04 Million |
Other Financing Activities | 27.02 Million | 8.6 Million | 29.35 Million | 3.56 Million | 6.8 Million | 4.38 Million |
Accounts receivables | -720 Thousand | 181 Thousand | -315 Thousand | -218.69 Thousand | 522.96 Thousand | -833.32 Thousand |
Accounts payables | -599 Thousand | 944 Thousand | 1.28 Million | -736.15 Thousand | 164.23 Thousand | 96.14 Thousand |
Inventory | 240 Thousand | -41 Thousand | 347 Thousand | -170.07 Thousand | 133.01 Thousand | - |
Other working capital | -2 Million | 1.96 Million | 367 Thousand | -35.06 Thousand | -360.76 Thousand | 306.06 Thousand |
Cash at beginning of period | 4.81 Million | 10.84 Million | 7.15 Million | 708.67 Thousand | 1.55 Million | 11.56 Million |
Cash at end of period | 2.38 Million | 4.81 Million | 10.84 Million | 7.15 Million | 708.67 Thousand | 1.55 Million |
Capital Expenditure | -5.12 Million | -111 Thousand | -117 Thousand | -632.45 Thousand | -16.82 Thousand | -1.22 Million |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | -2.42 Million | -6.03 Million | 3.69 Million | 6.44 Million | -849.72 Thousand | -10 Million |
Free Cash Flow | -29.27 Million | -24.17 Million | -20.22 Million | -15.8 Million | -8.53 Million | -14.39 Million |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | -6.27 Million | -7.59 Million | -22.11 Million | -6.53 Million | -8.34 Million | -4.79 Million |
Depreciation & Amortization | 651 Thousand | 629 Thousand | 2.36 Million | 603 Thousand | 606 Thousand | 598 Thousand |
Deferred income taxes | - | - | 1.07 Million | -607 Thousand | 1.8 Million | -1.19 Million |
Stock-based compensation | 269 Thousand | 334 Thousand | 2.72 Million | 706 Thousand | 843 Thousand | 731 Thousand |
Change in working capital | 1.56 Million | -2.04 Million | -3.08 Million | 85 Thousand | -1.94 Million | -181 Thousand |
Other non-cash items | 982 Thousand | 3.57 Million | 4.48 Million | 72 Thousand | 92 Thousand | 111 Thousand |
Investing Cash Flow | -869 Thousand | -894 Thousand | -5.12 Million | -1.53 Million | -1.43 Million | -1.38 Million |
Investments in PPE | -869 Thousand | -894 Thousand | -5.12 Million | -1.53 Million | 3000.00 | -18 Thousand |
Acquisitions | - | - | - | - | - | - |
Investment purchases | - | -894 Thousand | -4.66 Million | -4.33 Million | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | -865 Thousand | -894 Thousand | 4.66 Million | 2.8 Million | -1.43 Million | -1.36 Million |
Financing Cash Flow | 5.03 Million | 9.71 Million | 26.84 Million | 5.2 Million | 7.14 Million | 9.57 Million |
Debt repayment | - | -2.64 Million | -677 Thousand | -950 Thousand | -273 Thousand | - |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | 5.03 Million | 7.06 Million | 26.17 Million | 4.25 Million | 7.42 Million | 9.54 Million |
Other Financing Activities | -1000.00 | -1000.00 | 27.02 Million | 26.76 Million | -3000.00 | 37 Thousand |
Accounts receivables | -414 Thousand | -1 Million | -720 Thousand | 4000.00 | -51 Thousand | -187 Thousand |
Accounts payables | 1.11 Million | -359 Thousand | -599 Thousand | 140 Thousand | 199 Thousand | -169 Thousand |
Inventory | -359 Thousand | -563 Thousand | 240 Thousand | 839 Thousand | -488 Thousand | 27 Thousand |
Other working capital | 1.22 Million | -117 Thousand | -2 Million | -898 Thousand | -1.6 Million | 148 Thousand |
Cash at beginning of period | 2.58 Million | 2.38 Million | 4.81 Million | 4.71 Million | 5.94 Million | 2.47 Million |
Cash at end of period | 2.72 Million | 2.58 Million | 2.38 Million | 2.38 Million | 4.71 Million | 5.94 Million |
Capital Expenditure | -869 Thousand | -894 Thousand | -5.12 Million | -1.53 Million | 3000.00 | -18 Thousand |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | 139 Thousand | 205 Thousand | -2.42 Million | -2.32 Million | -1.23 Million | 3.46 Million |
Free Cash Flow | -4.89 Million | -9.5 Million | -29.27 Million | -7.53 Million | -6.94 Million | -4.75 Million |
CRDL
0VAG
THS
HRIBF
FMAN
RATEGAIN